Crucially, we propose the therapeutic paradigm of rational combination therapy, demonstrating that USP43-high neoplasms exhibit enhanced vulnerability to synergistic tumoricidal efficacy when targeted with SLC7A11 inhibitors in concert with platinum-based agents like cisplatin. The gene discussed is USP43; the disease is neoplasm.